Literature DB >> 7635849

Effects of clozapine on smoking in chronic schizophrenic outpatients.

T P George1, M J Sernyak, D M Ziedonis, S W Woods.   

Abstract

BACKGROUND: The effects of clozapine administration on smoking were examined in chronic schizophrenic outpatients.
METHOD: Twenty-nine of 30 schizophrenic outpatients enrolled in a university-affiliated Community Mental Health Center clozapine clinic were retrospectively surveyed by semistructured questionnaire regarding smoking before and after clozapine administration.
RESULTS: Smokers comprised 62% (N = 18) of patients, and within this group, there was a significant decrease in reported daily cigarette use during clozapine treatment compared with level of use when patients had been treated with typical neuroleptics (1.67 +/- 1.13 vs. 1.26 +/- 0.72 packs/day, p = .025).
CONCLUSION: Clozapine may alter smoking behaviors in chronic schizophrenics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635849

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  34 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

2.  Is initiation of smoking associated with the prodromal phase of schizophrenia?

Authors:  Kaisa Riala; Helinä Hakko; Matti Isohanni; Anneli Pouta; Pirkko Räsänen
Journal:  J Psychiatry Neurosci       Date:  2005-01       Impact factor: 6.186

Review 3.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

Review 5.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

6.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011

Review 7.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

8.  Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

Review 9.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

10.  Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.

Authors:  Michelle R Lofwall; Paul A Nuzzo; Charles Campbell; Sharon L Walsh
Journal:  Exp Clin Psychopharmacol       Date:  2014-01-27       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.